NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 294 filers reported holding NEKTAR THERAPEUTICS in Q3 2019. The put-call ratio across all filers is 0.81 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $546,000 | -41.4% | 29,975 | +14.4% | 0.00% | -50.0% |
| Q2 2019 | $932,000 | -2.1% | 26,205 | -7.5% | 0.00% | 0.0% |
| Q1 2019 | $952,000 | -10.9% | 28,333 | -12.8% | 0.00% | -20.0% |
| Q4 2018 | $1,068,000 | -49.5% | 32,492 | -6.3% | 0.01% | -44.4% |
| Q3 2018 | $2,113,000 | +145.7% | 34,675 | +96.7% | 0.01% | +80.0% |
| Q2 2018 | $860,000 | -60.6% | 17,628 | -14.2% | 0.01% | -54.5% |
| Q1 2018 | $2,183,000 | – | 20,551 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |